Across the cohort, six fusion gene rearrangements were identified in cancers of the colon (TPM-NTRK1), bile duct (FGFR2), thyroid (BRAF) and prostate (ETV4-CLTC, and TMPRSS2-ERG) (Supplementary Table S13). This evidence concerns the gene BRAF and malignant colon neoplasm.